Mechanisms and parameters governing initial infection are highly uncertain and, for technical-and ethical reasons, cannot be measured in humans. In the provided software (www.systems-pharmacology.org/ prep-predictor) it is therefore possible to freely choose model parameters. In the simulations and results presented in the main manuscript, we assumed a severe bottleneck (only few viruses reach a target-cell environment, see 'exposure model' in the main text) combined with low viral clearance rates, as immune mediated clearance of HIV may not yet be in place (resulting in a large R 0 ). Biological arguments for these parameter choices are given at the end of this note and in the Discussion (main manuscript). In terms of modelling, these conditions can be considered conservative, as they might under-predict prophylactic efficacy, as will become evident in this text. While the main strength of our results (and modelling in general) is to rule out certain candidates, our parameters choice could falsely rule out some candidates that might be efficient clinically. However, and this is the main strength, it certainly provides a more rigorous scientific basis for those drug candidates that remain promising after this screen.
Sensitivity Analysis. The prophylactic efficacy is given by (compare with eq. (3), main article)
where P I = 1 − P E and (compare eq. (22) main article)
when considering cell-free (virus only) exposure, which we will do in the following. Rearranging eq. (S1.27) in Supplementary Text S1 we get
When putting everything together, we have
for the prophylactic efficacy. The equation above has three parameters that relate to the viral dynamics, namely the basic reproductive ratio R 0 , the virus inoculum V and the inverse of the expected number of viruses produced by a late infected T-cell T 2 , denoted by the fraction a 3 /a 6 . We will discuss this parameter at the very end of this Supplementary Note. In the sensitivity analysis we will focus on R 0 (∅) and the average inoculum sizeV since there is particular uncertainty around these parameters. Particularly,
will be computed as a function of the target cell density T u , which is a matter of debate with regard to the site of exposure (it has been argued to be small initially; discussion at the end of this note). Changes in T u affect reaction propensities a 4 (target cell infection) and to a lesser extent propensity a 1 (through target-cell dependent virus clearance), compare eq. (4) and (7) in the main article. We created a 15 × 15 grid, with log spaced values 1.6 · 10 9 < T u < 3.2 · 10 11 (which results in values 1.7 < R 0 (∅) < 112) and average inoculum sizes 0.1 <V < 1000. Using eq. (S2.2) we then compute the average transmission probability per exposureP trans ≈ P I (∅,V) in the absence of drugs and only retain those parameter sets, whereP trans is in a realistic range, e.g. 0.5% <P trans < 5% [1] [2] [3] [4] scenario. This means that it might under-predict prophylactic efficacy (the coloured lines are leftwards of the thick dotted line). In terms of screening for drug candidates (the practical utility of our tool), this parameter set is favourable: While some candidates may falsely be ruled out, because we under-predict their prophylactic potency, there is a much more rigorous scientific basis for those drug candidates that remain promising after this screen. CRAs make an exception: There are parameter configurations (9/45 reasonable parameter sets) that yield EC 50 s that exceed the ones we stated in the main manuscript. Therefore, for CRAs, we might over-or under-predict their efficacy. However, the only CRA tested, maraviroc (MRV), is not among the set of 5 compounds (EFV, NVP, ETR, RPV and DRV) which show promising concentration prophylaxis profile. For the moment, we cannot be certain about the prophylactic efficacy of MRV, but first clinical trial results indicate that it may not be potently enough on its own (see Discussion), which is in line with the predictions made in the main manuscript.
Biological plausibility of parameter choices. It is unclear, which physiological site is decisive for establishing irreversible infection. Some authors have argued that it is the vaginal submucosa during male → female transmission. In that context, it has been debated previously, that the target cell density at the site of viral exposure (e.g. vaginal submucosa) might initially be very low [5] . In terms of modelling, lower target cell densities strongly change (lower) reaction propensities a 4 (target cell infection) and to a lesser extent propensity a 1 (through target-cell dependent virus clearance). The net effect is that a lower proportion of viruses at the site of exposure will reach a target cell given by ζ = a 4 a 1 +a 4 . At the same time, exposure to semen and viruses, as well as inflammation may lead to the recruitment of target cells [5] shortly after exposure increasing the target cell availability. In essence, these considerations can be interpreted as follows: After breaching the mucosal barrier, there is a strong bottleneck, i.e. only a small proportion of viruses reach a target cell, denoted by ζ low . Subsequent generations of viruses may encounter higher target-cell densities due to the recruitment of target cells and therefore ζ low → ζ. This additional bottleneck can be either be modelled explicitly, or implicitly by fitting an exposure distribution that captures the infection risk (as in this study). Mathematically, for the first round of replication, we would have
, where 0 ≤ c ≤ 1 denotes the bottleneck from the first replication cycle, which is caused by a low target cell density. Due to target cell recruitment, ζ low → ζ in subsequent generations and hence R 0,low → R 0 . It is now either possible to model these processes explicitly, which however involves many unknowns and requires to consider a time-evolving R 0 . Or, it is possible to model these aspects implicitly as done in the current study, by fitting an exposure model to experimentally observed infection probabilities, which may already entail the bottleneck c. Another important aspect to consider is that it may be reasonable so assume that virus may not be cleared as efficiently shortly after the first virus exposure as compared to chronic infection. Essentially, the adaptive immune system may not yet recognise the virus during the first few days post-exposure. Current estimates of R 0 during infection are based on viral growth kinetics after the virus has become detectable (> 14 days after exposure). Interestingly, at this time point adaptive immune responses have developed [6] (unlike during exposure). Hence, R 0 during initial infection/immediately after exposure may be larger. In our modelling we assumed a low ability of the immune system to clear HIV, in line with the assumption that the adaptive immune system cannot yet efficiently remove HIV. This assumption results in large values for R 0 (∅) in our study. We did not depict the sensitivity analysis with respect to the average number of infectious viruses produced by a single late infected T-cell a 3 a 6 (∅) in eq. (S2.4). Note that a 3 has previously been determined from viral decay kinetics [7] to be around 1 day −1 , whereas a 6 (∅) has been determined to be 1000 per day or higher. Substituting a larger value of a 6 (∅) into eq. (S2.4) has the following effect for all drug classes: Their in vitro drug potency more strongly overestimates their PrEP potency, i.e. the drugs are less efficient in preventing HIV transmission than suggested by their IC 50 , lending further support to our statement that the measurable in vitro potency should not be used directly to guide clinical trial design.
